{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:12:06Z","timestamp":1793398326639,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Monoclonal antibodies (mAbs) targeting the Calcitonin Gene-Related Peptide (CGRP) pathway are safe and effective treatments for migraine prevention. However, the high cost of these novel therapies has led to reimbursement policies requiring patients to try multiple traditional preventives before access. In Germany, a recent change in insurance policy significantly expanded coverage for the CGRP receptor mAb erenumab, enabling migraine patients who failed just one prior prophylactic medication to receive this mAb. Here, we compare the clinical response to treatment with erenumab in migraine patients treated using the old and new coverage policy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective cohort study, we included CGRP-mAb na\u00efve patients with episodic or chronic migraine, who started erenumab at our headache center according to either the old or the new insurance policy and received at least 3 consecutive injections. Headache diaries and electronic documentation were used to evaluate reductions in monthly headache and migraine days (MHD and MMD) and\u2009\u2265\u200950% and\u2009\u2265\u200930% responder rates at month 3 (weeks 9\u201312) of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 146 patients who received erenumab according to the old policy and 63 patients that were treated using the new policy. At weeks 9\u201312 of treatment, 37.7% of the old policy group had a 50% or greater reduction in MHD, compared to 63.5% of the new policy group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Mean reduction in MHD was 5.02\u00a0days (SD\u2009=\u20095.46) and 6.67\u00a0days (SD\u2009=\u20095.32, <jats:italic>P<\/jats:italic>\u2009=\u20090.045) in the old and new policy cohort, respectively. After propensity score matching, the marginal effect of the new policy on treatment outcome was 2.29\u00a0days (standard error, SE: 0.715, <jats:italic>P<\/jats:italic>\u2009=\u20090.001) more reduction in MHD, and 30.1% (SE: 10.6%, <jats:italic>P<\/jats:italic>\u2009=\u20090.005) increase in\u2009\u2265\u200950% response rate for MHD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Starting erenumab earlier in the course of migraine progression in a real-world setting may lead to a better response than starting after multiple failed prophylactic attempts. Continually gathering real-world evidence may help policymakers in deciding how readily to cover CGRP-targeted therapies in migraine prevention.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01682-2","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:02:57Z","timestamp":1698624177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Impact of a reimbursement policy change on treatment with erenumab in migraine \u2013 a real-world experience from Germany"],"prefix":"10.1186","volume":"24","author":[{"given":"Ja Bin","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin Sophie","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Fitzek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Hendrik","family":"Overeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Triller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Raffaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"1682_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP et al (2021) Migraine: epidemiology and systems of care. The Lancet 397:1485\u20131495. https:\/\/doi.org\/10.1016\/S0140-6736(20)32160-7","journal-title":"The Lancet"},{"key":"1682_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ, Hagen K, Linde M, Steiner TJ (2022) The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 23:34. https:\/\/doi.org\/10.1186\/s10194-022-01402-2","journal-title":"J Headache Pain"},{"key":"1682_CR3","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF et al (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35:478\u2013488. https:\/\/doi.org\/10.1177\/0333102414547138","journal-title":"Cephalalgia"},{"key":"1682_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI et al (2023) The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain 24:56. https:\/\/doi.org\/10.1186\/s10194-023-01594-1","journal-title":"J Headache Pain"},{"key":"1682_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M et al (2017) Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 97:553\u2013622. https:\/\/doi.org\/10.1152\/physrev.00034.2015","journal-title":"Physiol Rev"},{"key":"1682_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies \u2014 successful translation from bench to clinic. Nat Rev Neurol 14:338\u2013350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1","journal-title":"Nat Rev Neurol"},{"key":"1682_CR7","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. The Lancet 392:2280\u20132287. https:\/\/doi.org\/10.1016\/S0140-6736(18)32534-0","journal-title":"The Lancet"},{"key":"1682_CR8","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1007\/s12325-021-01911-7","volume":"38","author":"U Reuter","year":"2021","unstructured":"Reuter U, Lucas C, Dolezil D et al (2021) Galcanezumab in patients with multiple previous migraine preventive medication category failures: results from the open-label period of the CONQUER trial. Adv Ther 38:5465\u20135483. https:\/\/doi.org\/10.1007\/s12325-021-01911-7","journal-title":"Adv Ther"},{"key":"1682_CR9","doi-asserted-by":"publisher","first-page":"033310242311521","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, Huessler E-M, Puledda F et al (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia 43:03331024231152169. https:\/\/doi.org\/10.1177\/03331024231152169","journal-title":"Cephalalgia"},{"key":"1682_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, Ehrlich M, Gendolla A et al (2022) Erenumab versus topiramate for the prevention of migraine \u2013 a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 42:108\u2013118. https:\/\/doi.org\/10.1177\/03331024211053571","journal-title":"Cephalalgia"},{"issue":"7","key":"1682_CR11","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/ph16070934","volume":"16","author":"JB Hong","year":"2023","unstructured":"Hong JB, Lange KS, Overeem LH et al (2023) A scoping review and meta-analysis of anti-CGRP monoclonal antibodies: predicting response. Pharmaceuticals 16(7):934. https:\/\/doi.org\/10.3390\/ph16070934","journal-title":"Pharmaceuticals"},{"key":"1682_CR12","unstructured":"Bundesministerium f\u00fcr Gesundheit (2021) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie: Anlage XII \u2013 Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a des F\u00fcnften Buches Sozialgesetzbuch (SGB V) Erenumab"},{"key":"1682_CR13","unstructured":"The German Migraine and Headache Society (2019) Market launch and approval of antibodies directed against CGRP. https:\/\/www.dmkg.de\/files\/dmkg.de\/aktuelles\/DMKG_Info%20zu%20CGRP-AK_final.pdf"},{"key":"1682_CR14","doi-asserted-by":"publisher","unstructured":"International Headache Society (2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"1682_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/00401706.1962.10490038","volume":"4","author":"GEP Box","year":"1962","unstructured":"Box GEP, Tidwell PW (1962) Transformation of the Independent Variables. Technometrics 4:531\u2013550. https:\/\/doi.org\/10.1080\/00401706.1962.10490038","journal-title":"Technometrics"},{"key":"1682_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1037\/0012-1649.44.2.395","volume":"44","author":"EA Stuart","year":"2008","unstructured":"Stuart EA, Green KM (2008) Using full matching to estimate causal effects in nonexperimental studies: examining the relationship between adolescent marijuana use and adult outcomes. Dev Psychol 44:395\u2013406. https:\/\/doi.org\/10.1037\/0012-1649.44.2.395","journal-title":"Dev Psychol"},{"key":"1682_CR17","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/j.jtho.2020.11.030","volume":"16","author":"J Liang","year":"2021","unstructured":"Liang J, Hu Z, Zhan C, Wang Q (2021) Using propensity score matching to balance the baseline characteristics. J Thorac Oncol 16:e45\u2013e46. https:\/\/doi.org\/10.1016\/j.jtho.2020.11.030","journal-title":"J Thorac Oncol"},{"key":"1682_CR18","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2023","unstructured":"R Core Team (2023) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria"},{"key":"1682_CR19","volume-title":"RStudio: Integrated Development Environment for R","author":"Posit team,","year":"2022","unstructured":"Posit team, (2022) RStudio: Integrated Development Environment for R. Posit Software, PBC, Boston, MA"},{"key":"1682_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","volume":"42","author":"DE Ho","year":"2011","unstructured":"Ho DE, Imai K, King G, Stuart EA (2011) MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Soft 42:1\u201328","journal-title":"J Stat Soft"},{"key":"1682_CR21","unstructured":"Arel-Bundock V (2023) marginaleffects: Predictions, Comparisons, Slopes, Marginal Means, and Hypothesis Tests"},{"key":"1682_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/atm.2018.12.10","volume":"7","author":"Z Zhang","year":"2019","unstructured":"AME Big-Data Clinical Trial Collaborative Group, Zhang Z, Kim HJ et al (2019) Balance diagnostics after propensity score matching. Ann Transl Med 7:16\u201316","journal-title":"Ann Transl Med"},{"key":"1682_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update. J Headache Pain 23:67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"key":"1682_CR24","unstructured":"National Institute for Health and Care Excellence (2022) Fremanezumab for preventing migraine. In: Technology appraisal guidance [TA764]. https:\/\/www.nice.org.uk\/guidance\/ta764. Accessed 4 Sep 2023"},{"key":"1682_CR25","unstructured":"National Institute for Health and Care Excellence (2021) Erenumab for preventing migraine. In: Technology appraisal guidance [TA682]. https:\/\/www.nice.org.uk\/guidance\/ta682. Accessed 4 Sep 2023"},{"key":"1682_CR26","unstructured":"National Institute for Health and Care Excellence (2020) Galcanezumab for preventing migraine. https:\/\/www.nice.org.uk\/guidance\/ta659. Accessed 4 Sep 2023"},{"key":"1682_CR27","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.37765\/ajmc.2023.89352","volume":"29","author":"L Musial","year":"2023","unstructured":"Musial L, Kheloussi S (2023) Prior authorization requirements for calcitonin gene-related peptide antagonists. Am J Manag Care 29:e117\u2013e123","journal-title":"Am J Manag Care"},{"key":"1682_CR28","unstructured":"Canadian Drug Expert Committee (2020) Erenumab (Aimovig) - CDEC Final Recommendation. In: SR0578\u2013000. https:\/\/www.cadth.ca\/erenumab"},{"key":"1682_CR29","first-page":"1","volume":"2","author":"Reimbursement Team","year":"2022","unstructured":"Reimbursement Team (2022) CADTH Reimbursement Recommendation Galcanezumab (Emgality). Can J Med Technol 2:1\u201317","journal-title":"Can J Med Technol"},{"key":"1682_CR30","unstructured":"Canadian Drug Expert Committee (2021) Fremanezumab (Ajovy) - CDEC Final Recommendation. In: SR0641\u2013000. https:\/\/www.cadth.ca\/fremanezumab"},{"key":"1682_CR31","first-page":"123","volume":"73","author":"X Moisset","year":"2023","unstructured":"Moisset X, Demarquay G (2023) Anti-calcitonin generelated peptide (CGRP) therapies for migraine. Rev Prat 73:123\u2013126","journal-title":"Rev Prat"},{"key":"1682_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37:470\u2013485. https:\/\/doi.org\/10.1177\/0333102416678382","journal-title":"Cephalalgia"},{"key":"1682_CR33","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.clinthera.2008.12.010","volume":"30","author":"AZ Yaldo","year":"2008","unstructured":"Yaldo AZ, Wertz DA, Rupnow MFT, Quimbo RM (2008) Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting. Clin Ther 30:2452\u20132460. https:\/\/doi.org\/10.1016\/j.clinthera.2008.12.010","journal-title":"Clin Ther"},{"key":"1682_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. JMCP 20:22\u201333","journal-title":"JMCP"},{"key":"1682_CR35","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12883-023-03302-7","volume":"23","author":"N Siersb\u00e6k","year":"2023","unstructured":"Siersb\u00e6k N, Kilsdal L, Jervelund C et al (2023) Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine. BMC Neurol 23:254. https:\/\/doi.org\/10.1186\/s12883-023-03302-7","journal-title":"BMC Neurol"},{"key":"1682_CR36","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40273-020-00996-2","volume":"39","author":"R Mahon","year":"2021","unstructured":"Mahon R, Lang A, Vo P et al (2021) Cost-effectiveness of erenumab for the preventive treatment of migraine in patients with prior treatment failures in Sweden. Pharmacoeconomics 39:357\u2013372. https:\/\/doi.org\/10.1007\/s40273-020-00996-2","journal-title":"Pharmacoeconomics"},{"key":"1682_CR37","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.jval.2021.04.1281","volume":"24","author":"AH Seddik","year":"2021","unstructured":"Seddik AH, Schiener C, Ostwald DA et al (2021) Social impact of prophylactic migraine treatments in Germany: a state-transition and open cohort approach. Value in Health 24:1446\u20131453. https:\/\/doi.org\/10.1016\/j.jval.2021.04.1281","journal-title":"Value in Health"},{"key":"1682_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-023-01556-7","volume":"24","author":"K Ihara","year":"2023","unstructured":"Ihara K, Ohtani S, Watanabe N et al (2023) Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study. J Headache Pain 24:23. https:\/\/doi.org\/10.1186\/s10194-023-01556-7","journal-title":"J Headache Pain"},{"key":"1682_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.805334","volume":"12","author":"J Schoenen","year":"2021","unstructured":"Schoenen J, Timmermans G, Nonis R et al (2021) Erenumab for migraine prevention in a 1-year compassionate use program: efficacy, tolerability, and differences between clinical phenotypes. Front Neurol 12:805334. https:\/\/doi.org\/10.3389\/fneur.2021.805334","journal-title":"Front Neurol"},{"key":"1682_CR40","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1177\/03331024211008401","volume":"41","author":"L Pazdera","year":"2021","unstructured":"Pazdera L, Cohen JM, Ning X et al (2021) Fremanezumab for the preventive treatment of migraine: subgroup analysis by number of prior preventive treatments with inadequate response. Cephalalgia 41:1075\u20131088. https:\/\/doi.org\/10.1177\/03331024211008401","journal-title":"Cephalalgia"},{"key":"1682_CR41","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/ene.14114","volume":"27","author":"DD Ruff","year":"2020","unstructured":"Ruff DD, Ford JH, Tockhorn-Heidenreich A et al (2020) Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials. Euro J of Neurology 27:609\u2013618. https:\/\/doi.org\/10.1111\/ene.14114","journal-title":"Euro J of Neurology"},{"key":"1682_CR42","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/0333102419835459","volume":"39","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Paemeleire K, Broessner G et al (2019) Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 39:817\u2013826. https:\/\/doi.org\/10.1177\/0333102419835459","journal-title":"Cephalalgia"},{"key":"1682_CR43","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/head.14459","volume":"63","author":"A Ezzati","year":"2023","unstructured":"Ezzati A, Fanning KM, Reed ML, Lipton RB (2023) Predictors of treatment-response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti-inflammatory drugs in acute treatment of episodic migraine. Headache 63:342\u2013352. https:\/\/doi.org\/10.1111\/head.14459","journal-title":"Headache"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01682-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01682-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01682-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:03:10Z","timestamp":1698624190000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01682-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1682"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01682-2","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"assertion":[{"value":"25 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Charit\u00e9 Ethical Committee (EA1\/159\/22). Written informed consent was not required due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}